1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Foundation Medicine, Inc., Genentech, Incyte, Merck Sharp & Dohme Corp. and NantHealth, Inc.
1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application


PER Pulse™ Recap

Resources

Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application
Earn up to 2.0 AMA PRA Category 1 Credits™
Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™ is an online continuing medical education (CME)‒certified activity.

PER Pulse™ Recap
PER Pulse™ Recaps for Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer


PER Pulse™ Recap

PER Pulse™ Recap



1 of 3
PER Pulse™ Recap

Immunotherapy as a Standard of Care in Lung Cancer

The 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, held December 10, 2016, provided a comprehensive review of key data sets regarding the use of immunotherapies in multiple tumor types. This first of 3 PER Pulse™ Recaps from the meeting focuses on the rapid establishment of immune checkpoint inhibitors in treatment algorithms for patients with non–small cell lung cancer (NSCLC).

The approval of single-agent therapies represents the first phase of lung cancer immunotherapy, although these approvals have had a major impact. In 2016, pembrolizumab received approval, based on data from the KEYNOTE-024 trial, as first-line therapy in patients with PD-L1-positive (≥50%) NSCLC. Also in 2016, the anti–PD-L1 antibody atezolizumab was approved for use in platinum-pretreated patients based on the results of randomized trials, including OAK. Both pembrolizumab and atezolizumab demonstrated superior efficacy compared with standard chemotherapy in the respective settings.

Immunotherapy-based combinations are a key component of the next phase of development, as demonstrated by early phase data. Results of the KEYNOTE-021 trial showed an improvement in overall response rate and progression-free survival with the addition of pembrolizumab to pemetrexed/carboplatin in patients with previously untreated NSCLC and adenocarcinoma histology; the combination regimen is currently under regulatory review. In addition, the blockade of PD-1/PD-L1 and CTLA-4 checkpoints has been explored with the combinations of nivolumab/ipilimumab (CheckMate 012) and durvalumab/tremelimumab. These are currently in phase 3 investigation.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, including downloadable slides from the meeting.



2 of 3
PER Pulse™ Recap

The Rapid Rise of Immune Checkpoint Inhibitors in Advanced Bladder Cancer

The 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, held December 10, 2016, provided a comprehensive review of key data sets regarding the use of immunotherapies in multiple tumor types. This second of 3 PER Pulse™ Recaps from the meeting focuses on the emergence of immunotherapy in patients with advanced bladder cancer.

The platinum-pretreated setting of advanced bladder cancer has received major attention from developers of immunotherapy, with atezolizumab receiving approval in May 2016, followed by nivolumab in February 2017. At least 3 other antibodies (avelumab, durvalumab, and pembrolizumab) are in regulatory review for patients with platinum-pretreated bladder cancer, with decisions anticipated by mid-2017.

In the frontline setting, immunotherapy is being explored as treatment for patients who are ineligible to receive cisplatin. Currently, atezolizumab and pembrolizumab are in review for this indication, with decisions expected in April 2017 and June 2017, respectively.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, including downloadable slides from the meeting.


3 of 3
PER Pulse™ Recap

Immunotherapy in Cutaneous Malignancies and Head and Neck Cancer

The 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, held December 10, 2016, provided a comprehensive review of key data sets regarding the use of immunotherapies in multiple tumor types. This third of 3 PER Pulse™ Recaps from the meeting focuses on recent developments with immunotherapy in Merkel cell carcinoma (MCC), melanoma, and head and neck squamous cell carcinoma (HNSCC).

Demonstrating the broad reach of immunotherapy, patients with the relatively uncommon MCC now have avelumab, an anti–PD-L1 antibody, which received accelerated approval from the FDA in March 2017. This indication also applies to patients who have not previously received chemotherapy. The anti–PD-1 antibody, pembrolizumab, has also demonstrated activity as first-line systemic therapy in patients with MCC.

In melanoma, a major developmental frontier is the investigation of novel combinations. These include combinations of immune checkpoint inhibitors with epacadostat, which inhibits the immunosuppressive enzyme indoleamine 2, 3-dioxygenase, as well as combinations with BRAF and MEK inhibitors.

For patients with recurrent/metastatic, platinum-pretreated HNSCC, 2 antibodies were approved in 2016. Pembrolizumab received accelerated approval in August 2016 based on the response rate in the KEYNOTE-012 trial. And in November 2016, nivolumab received approval based on an overall survival benefit compared with investigator’s choice therapy in the CheckMate 141 study.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, including downloadable slides from the meeting.



Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By